4D Molecular Therapeutics Change in Accounts Payable 2020-2025 | FDMT

4D Molecular Therapeutics change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

4D Molecular Therapeutics Change in Accounts Payable 2020-2025 | FDMT

4D Molecular Therapeutics change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$79.5B
Zoetis (ZTS)$68B
Daiichi Sankyo, - (DSNKY)$46.9B
Takeda Pharmaceutical (TAK)$46.6B
BeOne Medicines - (ONC)$32.5B
Sandoz Group AG (SDZNY)$26.5B
Summit Therapeutics (SMMT)$20.5B
Merck (MKKGY)$17.3B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$11.1B
Stevanato Group S.p.A (STVN)$8.5B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Procaps Group, S.A (PROCF)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B